LuisGarcía-‐Sevillano
146
Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology
Register cohorts. ArthritisRheum63, 26-‐36(2011).
27. Olsson, A.R.; Skogh, T.; Axelson, O.; Wingren, G. Occupations and exposures in the work
environment as determinants for rheumatoid arthritis. Occup Environ Med 61, 233-‐238
(2004).
28. Jin, Z.; Xiang, C.; Cai, Q.; Wei, X.; He, J. A
developing rheumatoid arthritis: a dose-‐
.
Ann RheumDis (2013). Disponible en:
-‐
203323
29. Ag
-‐
spe
unol 45, 256-‐266 (2013). Disponible
en:
30. Fes
; Weisman, M. H.; Buckner, J. H.; et al.
Pla
ciatedwithrheumatoidarthritis (RA)-‐
related autoantibodies in individuals at elevated risk for RA. J Rheumatol36, 943-‐946
(2009).
31. Calviello, G.; Su,H. M.; Weylandt, K. H.; Fasano, E.; Serini, S.; Cittadini, A. Experimental
Evidence of -‐3 Polyunsaturated Fatty Acid Modulation of Inflammatory Cytokines and
l Role in Inflammatory, Neurodegenerative, and
Int 743171,
(2013).
Disponible en:
32.
ine n-‐3 polyunsaturated fatty acids on immune
ts on clinical outcomes in rheumatoid
),
171-‐184 (2012).
Disponible en:
33.
rheumatoid arthritis: a review of the
).
34. Costenbader, K.H.; Kang, J.H.; Karlson, E. W. Antioxidant intake and risks of rheumatoid
arthritis and systemic lupus erythematosus in women. Am J Epidemiol 172,205-‐216
(2010).
35. Scher, J.U.; Ubeda, C.; Equinda,M.; Khanin, R.; Buischi, Y.; Viale, A.; et al. Periodontal disease
and the oral microbiota in new-‐onset rheumatoid arthritis. Arthritis Rheum 64, 3083-‐
3094(2012).
36. Mangat, P.; Wegner, N.; Venables, P.J.; Potempa, J. Bacterial and human
edeiminases: targets for inhibiting the autoimmune response in rheu
Arthritis Res Ther 12,
209(2010).
Disponible en:
-‐
research.com/content/12/3/209.
37. Hitchon, C. A.; El-‐Gabalawy, H.S. Infection and rheumatoid arthritis: still a
.
CurrOpinRheumatol 23, 352-‐357(2011).
38. Van denOever, I. A.; van Sijl, A. M.; Nurmohamed, M. T.Management of cardiovascular risk
ence and expert opinion. Ther Adv
(2013).
Disponible
en:
.
39.
besity is associated with worse disease
h co-‐morbidities—a long-‐term follow-‐up
from disease onset.
Arthritis Care Res 65,
78-‐87 (2013).
Disponible
en:http://dx.doi.org/10.1002/acr.21710.
40. Wolfe, F.; Michaud, K. Effect of body mass index on mortality and clinical status in
rheumatoidarthritis. ArthritisCareRes64, 1471-‐1479(2012).
41. Stavropoulos-‐Kalinoglou, A.; Metsios, G. S.; Panoulas, V. F.; Nightingale, P.; Koutedakis,Y.;
Kitas, G. D. Anti-‐tumo
tivity in normal-‐
weight but not in ob
s Ther 14, R160
(2012).Disponibleen:
42. Isaacs, J. D. The changi
for all?. Nat Rev
Inmunol10, 605-‐611(
43. Goronzy, J. J.; Weyand, C. M. Developments in the scientific understandin
arthritis. Arthritis Res Ther 11, 249 (2009). Disponible en:
‐
research.com/content/11/5/249.
